From The Florida Times-Union:
"The Mayo Clinic in Jacksonville has received a $41 million federal grant for a potentially groundbreaking study to better understand Alzheimer's disease and how the brain disorder affects people of different ethnic groups. The five-year grant from the National Institute on Aging, part of the National Institutes of Health, is one of the largest in the Jacksonville clinic's history. It will involve at least 80 researchers, from Mayo, Indiana University and 11 other U.S. institutions, and data from thousands of patients.
"Alzheimer's disease afflicts patients from African-American backgrounds at a rate twice as high as that in white populations. For Latino Americans, the risk is one-and-a-half times greater than that in white populations. These populations have traditionally been understudied for Alzheimer's disease, leading to a major knowledge gap. When we try to understand the molecular underpinnings, the disease fingerprints, we need to understand it for all of us to be able to identify biomarkers and therapies." Dr. Nilüfer Ertekin-Taner, a Mayo Clinic professor of neuroscience and neurology and physician-scientist who is a co-principal investigator of the study."
Through our support of this and other studies, GHR lives out its commitment to helping patients and families live full lives in a world where Alzheimer’s Disease becomes a preventable condition. GHR aims to halt Alzheimer's disease prior to the onset of cognitive symptoms by supporting new diagnostic tools and prevention trials. Learn more about our work on Alzheimer’s prevention.
"The Mayo Clinic in Jacksonville has received a $41 million federal grant for a potentially groundbreaking study to better understand Alzheimer's disease and how the brain disorder affects people of different ethnic groups. The five-year grant from the National Institute on Aging, part of the National Institutes of Health, is one of the largest in the Jacksonville clinic's history. It will involve at least 80 researchers, from Mayo, Indiana University and 11 other U.S. institutions, and data from thousands of patients.
"Alzheimer's disease afflicts patients from African-American backgrounds at a rate twice as high as that in white populations. For Latino Americans, the risk is one-and-a-half times greater than that in white populations. These populations have traditionally been understudied for Alzheimer's disease, leading to a major knowledge gap. When we try to understand the molecular underpinnings, the disease fingerprints, we need to understand it for all of us to be able to identify biomarkers and therapies." Dr. Nilüfer Ertekin-Taner, a Mayo Clinic professor of neuroscience and neurology and physician-scientist who is a co-principal investigator of the study."
Through our support of this and other studies, GHR lives out its commitment to helping patients and families live full lives in a world where Alzheimer’s Disease becomes a preventable condition. GHR aims to halt Alzheimer's disease prior to the onset of cognitive symptoms by supporting new diagnostic tools and prevention trials. Learn more about our work on Alzheimer’s prevention.
RSS Feed
